mTOR – a central growth regulator with a clearly defined biological role
mTOR (mechanistic Target of Rapamycin) is a central regulator of anabolic processes in the human body. It governs cell growth, protein synthesis, and tissue formation. Without mTOR, wound healing, classical regeneration, and adaptive responses to physical stress would not be possible.
The biological challenge, therefore, does not lie in mTOR itself, but in the lack of proper periodization of its activity. Under modern living conditions—with near-constant food availability, frequent insulin spikes, and a continuous energy supply—mTOR often remains active longer than biologically intended for a healthy balance between growth and renewal.
Why chronically elevated mTOR activity can limit repair processes and increase risk
Autophagy and mitophagy are cellular repair mechanisms that preferentially occur during phases of reduced mTOR activity. During these phases, damaged, dysfunctional, or energetically inefficient cellular components are selectively broken down and recycled.
If mTOR remains dominant for prolonged periods, this may:
- hinder the initiation of autophagic processes,
- reduce metabolic flexibility,
- impair mitochondrial efficiency,
- promote pro-inflammatory signaling pathways.
This does not represent a pathological state per se. Rather, it reflects the absence of sufficient reparative counterphases associated with reduced mTOR activity. Growth and repair are biologically complementary processes—they must occur at different times to support long-term cellular health.
Fasting as a physiological signal for mTOR modulation
Fasting represents an evolutionarily conserved mechanism that promotes these reparative phases. When nutrient intake is absent, several key metabolic signals shift:
- insulin and IGF-1 levels decline,
- the ATP/AMP ratio changes,
- AMPK is activated,
- mTOR activity is temporarily reduced,
- autophagic processes are upregulated.
The goal is not to completely suppress mTOR, but to reestablish a rhythmic alternation between growth and repair. In this context, fasting functions less as a dietary intervention and more as a metabolic regulatory signal.
Limitations of fasting in clinical practice
Despite its physiological logic, fasting is not equally suitable for all individuals. In clinical reality, extended fasting periods may carry risks—particularly in patients with pronounced fatigue, unstable metabolic conditions, a history of eating disorders, advanced age, or complex medication regimens.
For these populations, modulating mTOR activity and supporting autophagic processes would be beneficial in principle—but fasting is not always the safest or most practical approach.
Intermittent Hypoxia Training (IHT/IHHT) as an alternative path to metabolic periodization
Intermittent Hypoxia Training (IHT/IHHT) uses controlled, short-term hypoxic phases as a physiological stimulus. Reduced oxygen availability creates a temporary energetic challenge at the cellular level.
Research indicates that hypoxic stimuli can:
- activate AMPK-dependent signaling pathways,
- stimulate metabolic efficiency mechanisms,
- create conditions that favor autophagic processes,
- indirectly contribute to modulation of mTOR-related signaling axes.
The key point:
These effects can occur without nutrient deprivation. IHT/IHHT does not replace fasting, but it provides an alternative, technology-supported access to central regenerative signaling pathways.
Clinical value: making repair processes deliberately accessible
From a therapeutic perspective, the value of IHT/IHHT lies in its controllability. Duration, intensity, and frequency of hypoxic phases can be tailored to individual needs, monitored, and integrated into existing treatment protocols.
In this way, a principle previously known primarily as a lifestyle intervention is translated into a clinically manageable strategy.
Conclusion: shared biology, different access routes
- mTOR is essential for growth and adaptation—but requires reparative counterphases.
- Fasting supports this rhythm naturally.
- IHT/IHHT can open similar regenerative signaling environments via AMPK-dependent mechanisms.
Both approaches act on the same core metabolic pathways. They are not contradictory, but complementary.
How IHHT protocols are designed to safely and effectively utilize mTOR rhythm and autophagy is explained in detail and with clinical relevance in our online course.
Preview: another potential pathway to cellular repair
Beyond fasting and hypoxic stimuli, current research is exploring another possible approach that may influence similar signaling domains at the molecular level: molecular hydrogen (H₂).
Initial preclinical and experimental studies suggest that H₂ may possess antioxidant and inflammation-modulating properties and could affect signaling pathways relevant to autophagy, mitochondrial function, and the AMPK/mTOR axis. At present, these findings are not definitive, are largely based on animal and cell models, and must be clearly distinguished from established clinical applications.
Because this represents a biologically plausible but still critically evolving field, we address molecular hydrogen in a dedicated article—examining only peer-reviewed scientific publications, clearly labeling hypotheses as such, and providing a balanced assessment of the current evidence.
Marion Massafra-Schneider
